AC
ORMP icon

Armistice Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Armistice Capital’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-542,944
Closed -$1.63M – 79
2018
Q4 		$1.63M Sell
542,944
-81,056
-13% -$336K 0.12% 58
2018
Q3 		$3.04M Buy
+624,000
New +$3.24M 0.18% 67

Other funds holding ORMP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
RPC
Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Armistice Capital's ORMP Position: Q1 2019 in Review

Armistice Capital sold out of Oramed Pharmaceuticals (ORMP) in Q1 2019, closing a stake of 542,944 shares — an estimated $1.63M sold.

Armistice Capital first reported a position in ORMP in Q3 2018 and held it in 2 quarters. The position peaked at $3.04M in Q3 2018. 25 funds tracked by Wall St. Rank hold ORMP as of Q1 2019.

  • Armistice Capital reported no remaining Oramed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Armistice Capital sold 542,944 Oramed Pharmaceuticals shares in Q1 2019, an estimated $1.63M.
  • Armistice Capital first reported a position in Oramed Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Armistice Capital's Oramed Pharmaceuticals position peaked at $3.04M in Q3 2018.
  • 25 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2019.

Based on Armistice Capital's 13F filing for Q1 2019, filed 15 May 2019.